{"filing":{"accession_number":"0001213900-26-068502","cik":"0002023311","ticker":"AAPG","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"ea0294738-6k_ascentage.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023311/000121390026068502/ea0294738-6k_ascentage.htm"},"events":[{"id":12251,"run_id":10815,"accession_number":"0001213900-26-068502","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.82,"summary":"Ascentage Pharma disclosed seventeen clinical updates from its core assets—olverembatinib (HQP1351) and lisaftoclax (APG-2575)—presented at the EHA2026 Congress, including efficacy and safety data from multiple Phase II and Phase III studies across hematologic malignancies. Key highlights include Phase III POLARIS-1 data showing 94.4% CR/CRi rate in Ph+ ALL and Phase II data supporting olverembatinib as second-line therapy in CML, representing material progress toward regulatory approval and commercial potential.","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9054,"accession_number":"0001213900-26-068502","item_number":"EX-99.1","item_title":"ea029473801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces clinical trial updates and poster presentations at the EHA2026 Congress for two core assets—olverembatinib and lisaftoclax—including efficacy and safety data from multiple ongoing Phase II and Phase III studies in hematologic malignancies. While the disclosure is operational in nature (clinical development progress rather than a discrete event like M\u0026A, executive change, or financial restatement), the breadth and specificity of positive clinical data across multiple indications and patient populations, combined with the company's emphasis on these as \"key assets\" with global registrational trials, would likely be material to investors assessing the company's pipeline value and development trajectory. The data supports advancement toward regulatory approval and commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:31:06.453502+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9055,"accession_number":"0001213900-26-068502","item_number":"EX-99.2","item_title":"ea029473801ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses seventeen clinical updates from Ascentage Pharma's core assets presented at the EHA2026 Congress, including efficacy and safety data from multiple ongoing Phase II and Phase III studies of olverembatinib (HQP1351) and lisaftoclax (APG-2575) across various hematologic malignancies. The presentation of positive clinical trial results—particularly the Phase III POLARIS-1 data showing 94.4% CR/CRi rate in Ph+ ALL, the Phase II data supporting olverembatinib as second-line therapy in CML, and the pediatric combination study results—represents a material operational and clinical milestone that would affect a reasonable investor's assessment of the company's pipeline progress and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:31:06.453502+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9054,"accession_number":"0001213900-26-068502","item_number":"EX-99.1","item_title":"ea029473801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces clinical trial updates and poster presentations at the EHA2026 Congress for two core assets—olverembatinib and lisaftoclax—including efficacy and safety data from multiple ongoing Phase II and Phase III studies in hematologic malignancies. While the disclosure is operational in nature (clinical development progress rather than a discrete event like M\u0026A, executive change, or financial restatement), the breadth and specificity of positive clinical data across multiple indications and patient populations, combined with the company's emphasis on these as \"key assets\" with global registrational trials, would likely be material to investors assessing the company's pipeline value and development trajectory. The data supports advancement toward regulatory approval and commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:31:06.453502+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-06-15"},{"id":9055,"accession_number":"0001213900-26-068502","item_number":"EX-99.2","item_title":"ea029473801ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses seventeen clinical updates from Ascentage Pharma's core assets presented at the EHA2026 Congress, including efficacy and safety data from multiple ongoing Phase II and Phase III studies of olverembatinib (HQP1351) and lisaftoclax (APG-2575) across various hematologic malignancies. The presentation of positive clinical trial results—particularly the Phase III POLARIS-1 data showing 94.4% CR/CRi rate in Ph+ ALL, the Phase II data supporting olverembatinib as second-line therapy in CML, and the pediatric combination study results—represents a material operational and clinical milestone that would affect a reasonable investor's assessment of the company's pipeline progress and regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:31:06.453502+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-06-15"}]}